Zymeworks Inc. (“Zymeworks” or the “Company”) (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that independent proxy advisory firm Glass, Lewis & Co. (“Glass Lewis”) has recommended that Zymeworks shareholders vote FOR the Company’s plan to become a Delaware corporation (the “Redomicile”).
September 16, 2022
· 9 min read